Moderna MRNA 深 沪
交易中 05-11 10:33:38 美东时间
57.083
+2.908
+5.37%
华盛通- 最 高59.48
- 今 开58.08
- 成交量 995.11万股
- 最 低 46.73
- 昨 收 54.175
- 总市值 2271.90万
- 52周最高 59.55
- 市盈率 静 2.02
- 换手率 2500.28%
- 52周最低 22.28
- 委 比 20.00%
- 总股本 0.00亿
- 历史最高 497.49
- 量 比 8.24
- 振 幅 23.53%
- 历史最低 1.10
- 每 手 1
- 风险率 10.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Babcock & Wilcox Stock Gains Following Strong Q1 Results
Babcock & Wilcox Enterprises shares are trading higher Monday after it reported better-than-expected first-quarter financial results.
今天 21:33
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb
Moderna and Novavax stocks climb as investors digest new cases in the hantavirus outbreak.
今天 21:29
IREN Shares Slide On Proposed $2 Billion Convertible Notes Offering
IREN Ltd is trading lower Monday morning after the company announced its intention to offer $2 billion in convertible senior notes due 2033.
今天 21:18
Keel Shares Under Pressure After Double Miss
Keel Infrastructure Corp. (NASDAQ: KEEL) shares are trading lower Monday after the company reported first-quarter financial results.
今天 21:09
Moderna Shares Surge On Hantavirus Concerns: What Investors Need To Know
Moderna shares are trading higher in Monday's pre-market as focus shifted to a hantavirus outbreak spotlighting its specialized pipeline.
今天 21:07
Why Digi Power X Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
DGXX up 19.5% in pre-market trading after increasing the offering program. EZGO, HPAI, MRAM, NVEC, WYFI, RXT, INV, GCTS, and MRNA are top gainers. HUBC, ONEG, SDOT, ENHA, PHOE, RPGL, and DTSS are top losers.
今天 18:05
Amprius Technologies (AMPX) Shares Plunge On Mixed Q1 Results, Weak EPS Guidance
Shares of Amprius Technologies are trading sharply lower Thursday afternoon. The sell-off follows the company's mixed first-quarter 2026 earnings report and an updated full-year outlook that disappointed investors on the bottom line.
05-08 00:18
Moderna Stock Gives Back Early Gains: What's Happening?
Moderna, Inc. (NASDAQ:MRNA) shares initially surged Thursday, but have since retreated after the company announced the publication of its Phase 3 study results evaluating mRNA -1010 in the New England Journal of Medicine.
05-07 22:59
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels highlight momentum and key price zones.
05-04 23:15
Moderna's Legal Hit Steals Spotlight From Strong Sales
MRNA revenue hits $389M, beating Wall Street estimates. Despite a Q1 loss, Moderna eyes 10% growth and new flu vaccine approvals in 2026.
05-01 22:44
